Table 2.

Sensitive analysis of the results of any adverse effects and clinical recovery

Outcome	Any adverse effects
Study omitted	RR	95% CI	I2	P-value*
Cavalcanti et al 2020 (HCQ alone)	1.45	1.02–1.89	51.8%	<0.001
Cavalcanti et al 2020 (HCQ+Azi)	1.37	1.11–1.63	45.9%	<0.001
Chen Jun et al 2020	1.46	1.09–1.83	51.9%	<0.001
Huang et al 2020	1.55	1.29–1.83	37.8%	<0.001
Lyngbakken et al 2020	1.55	1.21–1.89	34.5%	<0.001
Self et al 2020	1.48	1.09–1.87	51.4%	<0.001
Skipper et al 2020	1.34	1.01–1.69	31.1%	<0.001
Tang et al 2020	1.48	1.10–1.74	37.9%	<0.001
Outcome	Clinical recovery
Abd-Elsalam et al 2020	1.01	0.90–1.11	0.0%	>0.05
Cheng et al 2020	1.03	0.93–1.14	44.6%	>0.05
Huang et al 2020	1.02	0.92–1.13	47.0%	>0.05
Self et al 2020	1.03	0.93–1.14	44.6%	>0.05
Tang et al 2020	1.01	0.94–1.09	46.8%	>0.05
Zhaowei Chen et al 2020	1.00	0.93–1.08	21.4%	>0.05

* value for heterogeneity among studies assessed with Cochran’s Q test.